Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Roe speaks with ecancertv at ASH 2016 about genotyping and treatment outcomes for patients with myelodysplastic syndrome with T cell large granular lymphocyte proliferations (LGL).
She describes characterisation of patients by age and risk, with a greater response to lenalidomide from patients without LGL clonal types.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma in a resource constrained setting
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
OncoAlert Round Up for August 25th - 31st, 2023
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer